{"organizations": [], "uuid": "0caea77148dd7476f36f1cf57fc052ec085840f8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-rexahn-pharmaceuticals-collaborate/brief-rexahn-pharmaceuticals-collaborates-with-zhejiang-haichang-biotechnology-idUSFWN1PY124", "country": "US", "domain_rank": 408, "title": "BRIEF-Rexahn Pharmaceuticals Collaborates With Zhejiang Haichang Biotechnology", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.985, "site_type": "news", "published": "2018-02-08T21:17:00.000+02:00", "replies_count": 0, "uuid": "0caea77148dd7476f36f1cf57fc052ec085840f8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-rexahn-pharmaceuticals-collaborate/brief-rexahn-pharmaceuticals-collaborates-with-zhejiang-haichang-biotechnology-idUSFWN1PY124", "ord_in_thread": 0, "title": "BRIEF-Rexahn Pharmaceuticals Collaborates With Zhejiang Haichang Biotechnology", "locations": [], "entities": {"persons": [{"name": "rexahn", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-rexahn pharmaceuticals collaborates with zhejiang haichang biotechnology", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "rexahn pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Rexahn Pharmaceuticals Inc:\n* REXAHN PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ZHEJIANG HAICHANG BIOTECHNOLOGY CO., LTD. FOR THE DEVELOPMENT OF RX-0201 (ARCHEXIN®) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA\n* REXAHN PHARMACEUTICALS INC - IN CONNECTION WITH AGREEMENT WITH HAICHANG, REXAHN PLANS TO DISCONTINUE INTERNALLY FUNDED PROGRAMS OF ARCHEXIN\n* REXAHN PHARMACEUTICALS INC - REXAHN WILL ALSO CEASE ENROLLMENT IN CURRENT PHASE IIA CLINICAL STUDY OF ARCHEXIN IN METASTATIC RENAL CELL CARCINOMA\n* REXAHN PHARMACEUTICALS - ‍UNDER TERMS OF DEAL, HAICHANG WILL DEVELOP A NANO-LIPOSOMAL FORMULATION OF RX-0201 USING ITS PROPRIETARY QTSOME TECHNOLOGY​\n* REXAHN - PARTIES TO SHARE DOWNSTREAM LICENSING FEES, ROYALTIES PAID RELATED TO DEVELOPMENT,COMMERCIALIZATION OF NANO-LIPOSOMAL FORMULATION OF RX-0201 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T21:17:00.000+02:00", "crawled": "2018-02-09T16:47:18.004+02:00", "highlightTitle": ""}